NAB-PACLIEVA 100 mg contains Paclitaxel (protein-bound particles), also known as nab-paclitaxel. It is a chemotherapy (anticancer) drug in which paclitaxel is bound to human albumin nanoparticles. This formulation improves drug delivery to tumor cells and eliminates the need for solvent (Cremophor EL), reducing hypersensitivity reactions.

Nab-Paclitaxel Injection is used for treatment of:

1. Breast cancer (metastatic or locally advanced)

2. Non-small cell lung cancer (NSCLC) (with carboplatin)

3. Pancreatic cancer (metastatic, in combination with gemcitabine)

Common side effects:

• Hair loss (alopecia)

• Fatigue

• Nausea and vomiting

• Peripheral neuropathy

• Myelosuppression (neutropenia, anemia)

• Muscle and joint pain

Serious side effects:

• Severe neutropenia and infections

• Severe peripheral neuropathy

• Liver enzyme elevation

• Rare hypersensitivity reactions

No routine premedication required (unlike conventional paclitaxel).

Dosage depends on cancer type and patient tolerance.

Common dosing regimens:

• Breast cancer: 260 mg/m² IV over 30 minutes every 3 weeks

• NSCLC: 100 mg/m² IV on Days 1, 8, 15 of a 21-day cycle

• Pancreatic cancer: 125 mg/m² IV on Days 1, 8, 15 of a 28-day cycle

 Administered as intravenous infusion under oncologist supervision.

NOTE: This medicine should be taken only under a doctor’s supervision.